TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18996759

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding with truncal vagotomy (LGBTV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding alone (LGB)
Number of subjects: 50
Study: 16397182

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 0
Study: 15319103

Group type: EXPERIMENTAL
Intervention: Soft prefabricated orthoses
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Soft custom orthoses
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Semirigid biomechanical orthoses
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Semirigid prefabricated orthoses
Number of subjects: 874

Group type: COMPARATOR
Intervention: All orthoses types
Number of subjects: 874
Study: 10940701

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combined therapy (radiotherapy with neoadjuvant cisplatin)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 159
Study: 9324707

Group type: EXPERIMENTAL
Intervention: Counselling service for patients under a case management trial scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 8258615

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray (100 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 0
Study: 3910429

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (G-II)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard anaesthesia (G-I)
Number of subjects: 24
Study: 31275597

Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice daily)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 29913001

Group type: EXPERIMENTAL
Intervention: Rituximab (2 infusions of 375 mg/m2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tacrolimus (along with tapering alternate-day prednisolone for 12 months)
Number of subjects: 120
Study: 27150353

Group type: EXPERIMENTAL
Intervention: TM SPV (treadmill self-paced VO2max test)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bruce protocol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CE SPV (cycle ergometer self-paced VO2max test)
Number of subjects: 13
Study: 24913242

Group type: EXPERIMENTAL
Intervention: Intraoperative 1 mg morphine bolus (Group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intraoperative 2 mg morphine bolus (Group C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continuous epidural morphine infusion of 0.2 mg/h with 0.1% levobupivacaine via PCEA (all groups)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No intraoperative morphine loading (Group A)
Number of subjects: 48
Study: 21300723

Group type: EXPERIMENTAL
Intervention: Skeletal anchorage (Onplant or Orthosystem implant)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transpalatal bar
Number of subjects: 120
Study: 19925489

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 19171091

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Laparoscopic Burch colposuspension
Number of subjects: 97
Study: 16227788

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: didanosine/stavudine
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: nelfinavir
Number of subjects: 334

Group type: COMPARATOR
Intervention: zidovudine/lamivudine
Number of subjects: 334
Study: 12364844

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (Depakote)
Number of subjects: 40
Study: 10866044

Group type: EXPERIMENTAL
Intervention: Low glucosamine infusion (1.6 micromol x min(‐1) x kg(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High glucosamine infusion (5 micromol x min(‐1) x kg(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study: 9174428

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg subcutaneous implant 4-6 weeks preoperatively (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg subcutaneous implant 4-6 weeks preoperatively and repeated on the day of endometrial resection (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group A, no preoperative preparation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B and C (combined)
Number of subjects: 60
Study: 7910133

Group type: EXPERIMENTAL
Intervention: 6% N-acetyl-aspartyl glutamic acid (NAAGA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: NAAGA and Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: NAAGA
Number of subjects: 17
Study: 3033182

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 40
Study: 30414753

Group type: EXPERIMENTAL
Intervention: Children's Attraction to Physical Activity (CAPA) Scale
Number of subjects: 30
Study: 30268163

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oxygen (control)
Number of subjects: 90
Study: 27096623

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24518532

Group type: EXPERIMENTAL
Intervention: Yo Puedo intervention (conditional cash transfers and life skills sessions)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard services control arm
Number of subjects: 162
Study: 22147786

Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 19493958

Group type: EXPERIMENTAL
Intervention: modafinil (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: prazosin (3 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: modafinil (300 mg) and prazosin (3 mg) together
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 18207336

Group type: EXPERIMENTAL
Intervention: Brief Interventions (BIs)
Number of subjects: 408
Study: 16805932

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 120
Study: 12815555

Group type: EXPERIMENTAL
Intervention: Oxymetholone (50 mg bid)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Oxymetholone (50 mg tid)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 10886233

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8644400

Group type: EXPERIMENTAL
Intervention: Compression stockings (pressure effect of 54 mmHg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 30
Study: 31893951

Group type: EXPERIMENTAL
Intervention: Matrix‐associated autologous chondrocyte implantation (ACI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 102
Study: 30501521

Group type: EXPERIMENTAL
Intervention: Therapeutic suggestions during pre-surgery visit and audio recording during surgery
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Therapeutic suggestions
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 28029347

Group type: EXPERIMENTAL
Intervention: Medical nonfiction books
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonmedical fiction books
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study: 24570989

Group type: EXPERIMENTAL
Intervention: Machined neck implants (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rough, grooved neck implants (group 2)
Number of subjects: 40
Study: 22275251

Group type: EXPERIMENTAL
Intervention: Probable RBD (pRBD(+))
Number of subjects: 651

Group type: COMPARATOR
Intervention: Control group (pRBD(-))
Number of subjects: 651
Study: 21550314

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 2502
Study: 17549891

Group type: EXPERIMENTAL
Intervention: Vasopressin (1‐desamino‐8‐D‐arginin‐vasopressin)
Number of subjects: 26
Study: 16117817

Group type: EXPERIMENTAL
Intervention: Agomelatine (50 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12372132

Group type: EXPERIMENTAL
Intervention: 180 mg Fexofenadine (FEX)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 5 mg Desloratadine (DL)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 10535855

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cyclosporin A (CSA) to achieve whole blood trough levels of 120‐150 ng/ml
Number of subjects: 41
Study: 8001386

Group type: COMPARATOR
Intervention: Upper access sites (subclavian or internal jugular veins)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lower access site (femoral vein)
Number of subjects: 45
Study: 2187169

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg b.i.d. IM from the day before operation to the 7th postoperative day, n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcium heparin (5000 IU t.i.d. SC from the operation to the 7th postoperative day, n = 70)
Number of subjects: 120
Study: 382082

Group type: EXPERIMENTAL
Intervention: Intralipid
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10% glucose
Number of subjects: 10
Study: 31866211

Group type: EXPERIMENTAL
Intervention: Health for Hearts United intervention (3 treatment churches)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Comparison group (3 churches)
Number of subjects: 211
Study: 31519177

Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-segmental fixation combined with vertebroplasty (SSF + VP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29019873

Group type: COMPARATOR
Intervention: 3D mapping system without x-ray (Group 1)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: x-ray and 3D mapping system (Group 2)
Number of subjects: 342
Study: 25858200

Group type: EXPERIMENTAL
Intervention: Video clip on a smart phone for communication skills training
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 87
Study: 24058089

Group type: EXPERIMENTAL
Intervention: Tea-flavor liquor (TFL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water control (WC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Traditional Chinese liquor (TCL)
Number of subjects: 16
Study: 20830646

Group type: EXPERIMENTAL
Intervention: Action plans
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Coping plans
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Control group (no action plans or coping plans)
Number of subjects: 1273
Study: 19242485

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid and oral ibuprofen for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16445331

Group type: EXPERIMENTAL
Intervention: Conventional physical therapy and 35 minutes of CPM applications daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Conventional physical therapy and 2 hours of CPM applications daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional physical therapy only
Number of subjects: 81
Study: 15540744

Group type: EXPERIMENTAL
Intervention: Transdermal laser stimulation of the posterior tibial nerve, performed daily for 30 seconds over the SP6 acupuncture point for 12 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (sham device)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both treatment and control groups
Number of subjects: 56
Study: 11236073

Group type: EXPERIMENTAL
Intervention: Mirtazapine add on therapy to haloperidol 5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo add on therapy to haloperidol 5 mg
Number of subjects: 30
Study: 9286889

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microg/kg in 100 ml normal saline)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 21
Study: 8361794

Group type: EXPERIMENTAL
Intervention: High-iron content premature formula (15 mg/L)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low-iron content premature formula (3 mg/L)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Human milk mixed with liquid fortifier (1.7 mg/L)
Number of subjects: 3
Study: 3731212

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg loading dose on day 1, 4 mg/kg/day for 3 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no aminophylline treatment)
Number of subjects: 25
Study: 29310142

Group type: EXPERIMENTAL
Intervention: Noncephalic presentation
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Noncephalic presentation via cesarean delivery
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Noncephalic presentation via vaginal delivery
Number of subjects: 1943

Group type: COMPARATOR
Intervention: Cephalic presentation
Number of subjects: 1943
Study: 26787790

Group type: EXPERIMENTAL
Intervention: Distal approach
Number of subjects: 122

Group type: COMPARATOR
Intervention: Proximal approach
Number of subjects: 122
Study: 25632805

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23656848

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 19812581

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 p.p.m. decreasing to 2 p.p.m. for 24 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18782206

Group type: EXPERIMENTAL
Intervention: Immediate catheterization (no delay group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: 2 min delay catheterization (2 min delay group)
Number of subjects: 73
Study: 16085617

Group type: EXPERIMENTAL
Intervention: Zirconia head
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cobalt-chromium head
Number of subjects: 52
Study: 11915394

Group type: EXPERIMENTAL
Intervention: Computer-controlled anesthetic delivery system
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard injections
Number of subjects: 150
Study: 10396711

Group type: EXPERIMENTAL
Intervention: Ketamine 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine 150 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine 200 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol hypnosis
Number of subjects: 30
Study: 7484046

Group type: EXPERIMENTAL
Intervention: 30 ml of 1% prilocaine plus 6 mg morphine sulfate in 10 ml of 0.9% sodium chloride (P/M group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30 ml of 1% prilocaine plus 10 ml of 0.9% sodium chloride (P group)
Number of subjects: 20
Study: 2292535

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Number of subjects: 2448

Group type: COMPARATOR
Intervention: Comparative antibiotics
Number of subjects: 2448
Study: 12336988

Group type: EXPERIMENTAL
Intervention: Progestasert
Number of subjects: 382

Group type: COMPARATOR
Intervention: CuT 200
Number of subjects: 382
Study: 30672304

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 40
Study: 30932841

Group type: EXPERIMENTAL
Intervention: TPAD with a Closed-Loop Controller
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 0
Study: 28111044

Group type: EXPERIMENTAL
Intervention: Partial infrahepatic inferior vena cava clamping
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonclamping
Number of subjects: 90
Study: 26059872

Group type: EXPERIMENTAL
Intervention: Home visits with a general practitioner and municipal nurse within seven days of discharge focusing on medication, rehabilitation plan, functional level, and need for further health care initiatives.
Number of subjects: 531

Group type: COMPARATOR
Intervention: Standard health care services (Control).
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Home visits with a general practitioner and municipal nurse.
Number of subjects: 531
Study: 23463656

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion for 2 hours
Number of subjects: 12
Study: 21483704

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT), n=64
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT), n=62
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ICBT and CBGT
Number of subjects: 126
Study: 18083322

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy for pregnant substance users (MET‐PS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 200
Study: 17228550

Group type: EXPERIMENTAL
Intervention: Treatment with antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asking about self-harm
Number of subjects: 0
Study: 12918647

Group type: EXPERIMENTAL
Intervention: 8-week hydration intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no hydration intervention)
Number of subjects: 49
Study: 11737501

Group type: EXPERIMENTAL
Intervention: Development work including educational strand with open learning research materials and tutorial support; clinical research project development support with project development awards
Number of subjects: 473
Study: 9007493

Group type: EXPERIMENTAL
Intervention: 50 IU r‐HuEpo/kg, subcutaneously thrice weekly
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 100 IU r‐HuEpo/kg, subcutaneously thrice weekly
Number of subjects: 32

Group type: COMPARATOR
Intervention: Commercial cow's milk protein
Number of subjects: 32

Group type: COMPARATOR
Intervention: Human milk protein
Number of subjects: 32
Study: 8064580

Group type: EXPERIMENTAL
Intervention: Physical exercise training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nontraining (control)
Number of subjects: 35
Study: 3330115

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg tid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29152749

Group type: EXPERIMENTAL
Intervention: Topical nasal anesthetic (0.4 mL of 2% viscous lidocaine hydrochloride)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (nonanesthetic lubricant)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical nasal anesthetic
Number of subjects: 20
Study: 27503659

Group type: EXPERIMENTAL
Intervention: 250 mg REL plus 500 mg IMI
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: 125 mg REL plus 500 mg IMI
Number of subjects: 351

Group type: COMPARATOR
Intervention: 500 mg IMI alone
Number of subjects: 351
Study: 23860624

Group type: EXPERIMENTAL
Intervention: Age-tailored intervention (age-specific strategy training and short-term emotional focus)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Age-neutral intervention
Number of subjects: 386
Study: 22497773

Group type: EXPERIMENTAL
Intervention: ORIF using two point fixation by miniplates
Number of subjects: 100

Group type: COMPARATOR
Intervention: ORIF using three point fixation by miniplates
Number of subjects: 100
Study: 20133012

Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5% cream
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% cream
Number of subjects: 490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study: 18078737

Group type: EXPERIMENTAL
Intervention: Lower levels of anger control
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Anger control variable
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Enhanced cortisol secretion
Number of subjects: 98
Study: 15843940

Group type: EXPERIMENTAL
Intervention: Single purse-string CSM (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Double purse-string CSM (group 2)
Number of subjects: 100
Study: 14625812

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (3 x 3 MIU sc weekly) and oral ribavirin (1000/1200 mg po daily) for 24 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (3 x 3 MIU sc weekly) and oral ribavirin (1000/1200 mg po daily) for 48 weeks
Number of subjects: 37
Study: 10824642

Group type: EXPERIMENTAL
Intervention: Nasal splinting (Breathe‐Right)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise (maximal oxygen uptake treadmill test)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined effects of exercise and nasal splinting
Number of subjects: 12
Study: 8690831

Group type: EXPERIMENTAL
Intervention: ICI 204,636 (75 to 750 mg daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 1978490

Group type: EXPERIMENTAL
Intervention: Remoxipride alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remoxipride combined with ethanol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remoxipride combined with diazepam
Number of subjects: 12